Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced a significant expansion of ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

In conclusion, several Nifty 50 stocks, including Cipla, Sun Pharma and Infosys, experienced declines in Wednesday's trading ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good ...

As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India. Despite category dominance and decades of trust, Cipla is now playing catch ...

The classification was communicated to the company via email on 4 August 2025. The inspection was conducted under the USFDA's ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The company expects continued growth from respiratory product launches and emerging ...

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.

Drug major Cipla on Friday reported a 10 per cent increase in its consolidated profit after tax to ₹1,298 crore for the first ...

India's Cipla (CIPL.NS) said on Saturday that its manufacturing of the COVID-19 remdesivir drug was beginning to catch up with demand after the company sought to boost production amid a massive ...